RJFSA
BHVN

Raymond James Financial Services Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,497
Closed -$226K – 3457
2022
Q3 		$226K Sell
1,497
-159
-10% -$23.6K ﹤0.01% 2771
2022
Q2 		$241K Sell
1,656
-600
-27% -$76.6K ﹤0.01% 2755
2022
Q1 		$267K Sell
2,256
-15
-0.7% -$1.87K ﹤0.01% 2803
2021
Q4 		$313K Buy
2,271
+188
+9% +$23.9K ﹤0.01% 2682
2021
Q3 		$289K Sell
2,083
-97
-4% -$12.1K ﹤0.01% 2716
2021
Q2 		$212K Buy
+2,180
New +$177K ﹤0.01% 2980
2020
Q1 		– Sell
-6,979
Closed -$380K – 2991
2019
Q4 		$380K Buy
6,979
+84
+1% +$4.16K ﹤0.01% 2162
2019
Q3 		$288K Sell
6,895
-100
-1% -$4.22K ﹤0.01% 2274
2019
Q2 		$306K Sell
6,995
-704
-9% -$39.7K ﹤0.01% 2261
2019
Q1 		$396K Buy
7,699
+75
+1% +$3.24K ﹤0.01% 2038
2018
Q4 		$282K Hold
7,624
– – ﹤0.01% 2038
2018
Q3 		$286K Buy
7,624
+250
+3% +$9.2K ﹤0.01% 2310
2018
Q2 		$291K Buy
+7,374
New +$234K ﹤0.01% 2256

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Raymond James Financial Services Advisors's BHVN Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,497 shares — an estimated $226K sold.

Raymond James Financial Services Advisors first reported a position in BHVN in Q2 2018 and held it in 13 quarters. The position peaked at $396K in Q1 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Raymond James Financial Services Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,497 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $226K.
  • Raymond James Financial Services Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 13 quarters.
  • Raymond James Financial Services Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $396K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.